However, given that serum GFAP levels may be elevated in patients with neurodegenerative diseases or traumatic brain injury and no cut-offs have been defined to differentiate these pathologies, the utility of GFAP is currently limited [23,24]. The gene discussed is GFAP; the disease is neurodegenerative disease.